176 related articles for article (PubMed ID: 19792962)
1. New perspectives in cancer immunotherapy and immunomonitoring.
Umansky V; Malyguine A; Shurin M
Future Oncol; 2009 Sep; 5(7):941-4. PubMed ID: 19792962
[No Abstract] [Full Text] [Related]
2. Therapeutic cancer vaccine development: will it ride the wave of new immunomodulatory agents?
Eggermont AM
Cancer J; 2011; 17(5):276. PubMed ID: 21952275
[No Abstract] [Full Text] [Related]
3. Interpreting cancer vaccine clinical trials.
Dranoff G
J Gene Med; 1999; 1(2):80-3. PubMed ID: 10738571
[TBL] [Abstract][Full Text] [Related]
4. Tumor immunology top 10 list.
Finn OJ
Immunol Rev; 2008 Apr; 222():5-8. PubMed ID: 18363991
[No Abstract] [Full Text] [Related]
5. CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.
Diken M; Boegel S; Grunwitz C; Kranz LM; Reuter K; van de Roemer N; Vascotto F; Vormehr M; Kreiter S
Hum Vaccin Immunother; 2014; 10(10):3090-100. PubMed ID: 25483671
[No Abstract] [Full Text] [Related]
6. [Perspectives for tumour immunology: antigen-specific immunotherapy of malignant diseases].
Jäger E; Jäger D; Knuth A
Dtsch Med Wochenschr; 2001 Sep; 126(37):1011-6. PubMed ID: 11555776
[No Abstract] [Full Text] [Related]
7. A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism.
Nelson B
Cancer Cytopathol; 2014 Jan; 122(1):1-2. PubMed ID: 24424750
[No Abstract] [Full Text] [Related]
8. Therapeutic cancer vaccines.
Ward S; Dalgleish A
Vaccine; 2007 Sep; 25 Suppl 2():B1-3. PubMed ID: 17681649
[No Abstract] [Full Text] [Related]
9. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy: Cancer vaccines on the move.
Banchereau J; Palucka K
Nat Rev Clin Oncol; 2018 Jan; 15(1):9-10. PubMed ID: 28895570
[No Abstract] [Full Text] [Related]
11. Cancer-testis antigens: targets for cancer immunotherapy.
Chen YT; Old LJ
Cancer J Sci Am; 1999; 5(1):16-7. PubMed ID: 10188055
[No Abstract] [Full Text] [Related]
12. Bacteriology: a caring culture.
DeWeerdt S
Nature; 2013 Dec; 504(7480):S4-5. PubMed ID: 24352362
[No Abstract] [Full Text] [Related]
13. Optimizing dendritic cell-based immunotherapy for cancer.
Zhong H; Shurin MR; Han B
Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
[TBL] [Abstract][Full Text] [Related]
14. Vaccines targeting tumor vasculature: a new approach for cancer immunotherapy.
Croix BS
Cytotherapy; 2007; 9(1):1-3. PubMed ID: 17354097
[No Abstract] [Full Text] [Related]
15. Cancer vaccines and immunotherapy.
Tang H
Hum Vaccin; 2009 Oct; 5(10):666. PubMed ID: 19855174
[No Abstract] [Full Text] [Related]
16. Immunotherapy for cancer: focusing on developing treatments rather than drugs.
Sznol M
Curr Opin Investig Drugs; 2001 Jul; 2(7):957-8. PubMed ID: 11757798
[No Abstract] [Full Text] [Related]
17. IL-13 receptor-directed cancer vaccines and immunotherapy.
Nakashima H; Husain SR; Puri RK
Immunotherapy; 2012 Apr; 4(4):443-51. PubMed ID: 22512637
[TBL] [Abstract][Full Text] [Related]
18. [NY-ESO-1 and cancer immunotherapy].
Peng JR; Leng XS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
[TBL] [Abstract][Full Text] [Related]
19. New approaches to immunoprevention and immunotherapy of neoplasms.
Glushkov AN
Russ J Immunol; 2002 Oct; 7(3):219-28. PubMed ID: 12674931
[TBL] [Abstract][Full Text] [Related]
20. Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy.
Chouaib S
J Clin Invest; 2003 Mar; 111(5):595-7. PubMed ID: 12618511
[No Abstract] [Full Text] [Related]
[Next] [New Search]
